Robert Leasure, Jr. has been appointed president and chief executive officer and director of Bioanalytical Systems, Inc. (BASi), effective as of January 12, 2019.
 
Since September of 2016, Mr. Leasure has worked closely with the company’s management team to guide operations and assist BASi in restructuring and developing a growth strategy. Mr. Leasure has led the company’s turnaround, including the company’s refinancing, its acquisition of Seventh Wave Laboratories, and its expansion and growth plans over the last two years.
 
“I couldn’t be more excited to have such a strong leader and visionary as Mr. Leasure in this role,” said Dr. Gregory C. Davis, BASi’s chairman of the board. “He is a champion of our collaborative culture and has an incredible ability to motivate and energize our teams, partners, and clients. His vision, strategy, and successful execution track record are exactly what BASi needs as we enter our next phase of growth for the Company.”
 
“I am extremely proud of all that BASi has accomplished in the time I have worked with the Company and the strong team and foundation we are building together for the future. We have significantly more that we can accomplish in the highly-dynamic and evolving landscape of this industry,” said Mr. Leasure. “I am honored to have been selected to lead this organization and by the support I have received from the founders, board members, and associates. I look forward to the Company’s future success as we continue to grow and build this organization together.”